Chemistry Wealth Management LLC Boosts Stake in Zoetis Inc. $ZTS

Key Points

• Chemistry Wealth Management increased its Zoetis stake by 504.4% in the second quarter, bringing its holdings to 19,696 shares valued at approximately $1.42 million. Institutional investors collectively own 92.8% of the company.
• Zoetis beat quarterly EPS estimates with $1.87 per share, but revenue of $2.47 billion was slightly below expectations and essentially flat year over year. The company cut fiscal 2026 adjusted EPS guidance to $6.15–$6.25 and revenue guidance to $9.1–$9.3 billion.
• Shares recently traded near $72.53, close to their one-year low, while analysts maintain a consensus “Hold” rating and an average price target of $115.50. Zoetis also declared a quarterly dividend of $0.53 per share, representing a 2.9% annualized yield.

Chemistry Wealth Management LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 504.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,696 shares of the company's stock after acquiring an additional 16,437 shares during the period. Chemistry Wealth Management LLC's holdings in Zoetis were worth $1,415,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ZTS. Prosperity Bancshares Inc acquired a new stake in Zoetis in the fourth quarter valued at approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis in the 1st quarter valued at $28,000. Elyxium Wealth LLC purchased a new stake in Zoetis in the 4th quarter worth $32,000. Root Financial Partners LLC lifted its holdings in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Finally, Wellington Grp LLC grew its position in shares of Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company's stock valued at $32,000 after purchasing an additional 267 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Insiders Place Their Bets

In other news, Director Michael B. Mccallister bought 3,000 shares of the firm's stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director directly owned 24,524 shares of the company's stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of the company's stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 11,650 shares of company stock valued at $886,384 over the last ninety days. Company insiders own 0.22% of the company's stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $72.53 on Friday. The business's 50 day moving average price is $76.66 and its 200 day moving average price is $100.75. The company has a market cap of $30.41 billion, a price-to-earnings ratio of 11.95, a PEG ratio of 1.26 and a beta of 0.74. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 70.95% and a net margin of 27.49%.The company's revenue for the quarter was down .2% on a year-over-year basis. During the same period last year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts predict that Zoetis Inc. will post 6.43 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis's payout ratio is 34.93%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ZTS. UBS Group decreased their price target on shares of Zoetis from $85.00 to $80.00 and set a "neutral" rating on the stock in a research note on Friday. Citigroup dropped their price target on Zoetis from $145.00 to $112.00 and set a "buy" rating for the company in a research report on Monday, May 18th. Barclays decreased their price objective on Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 1st. HSBC dropped their target price on shares of Zoetis from $140.00 to $95.00 and set a "buy" rating for the company in a report on Monday, July 6th. Finally, Wall Street Zen lowered shares of Zoetis from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $115.50.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source